EXHIBIT 10.5 FIRST AMENDMENT TO SETTLEMENT AGREEMENT THIS FIRST AMENDMENT TO SETTLEMENT AGREEMENT ("First Amendment"), effective as of October 1, 2003, is made by and among Applera Corporation, a Delaware corporation, acting through its Applied...Settlement Agreement • November 9th, 2004 • Diagnostic Products Corp • In vitro & in vivo diagnostic substances
Exhibit 10.1 AGREEMENT OF SALE AND PURCHASEAgreement of Sale and Purchase • May 15th, 2003 • Diagnostic Products Corp • In vitro & in vivo diagnostic substances • California
AGREEMENT AND PLAN OF MERGER DATED AS OF APRIL 26, 2006 BY AND AMONG SIEMENS MEDICAL SOLUTIONS USA, INC. DRESDEN ACQUISITION CORPORATION AND DIAGNOSTIC PRODUCTS CORPORATIONMerger Agreement • May 1st, 2006 • Diagnostic Products Corp • In vitro & in vivo diagnostic substances • California
This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of April 26, 2006, is by and among Siemens Medical Solutions USA, Inc., a Delaware corporation (the “Purchaser”), Dresden Acquisition Corporation, a California corporation and a wholly-owned subsidiary of the Purchaser (“Merger Sub”), and Diagnostic Products Corporation, a California corporation (the “Company” and, together with the Purchaser and Merger Sub, the “Parties” and each, a “Party”).
STANDARD INDUSTRIAL LEASE OPTION EXERCISEStandard Industrial Lease • May 10th, 2005 • Diagnostic Products Corp • In vitro & in vivo diagnostic substances
This Exercise of Option is made with respect to that certain Standard Industrial Lease dated February 18, 1991 (the “Lease”) between 5700 West 96th Street, a California general partnership (“Lessor”), and Diagnostic Products Corporation, a California corporation (“Lessee”), as amended pursuant to that certain Second Addendum to Standard Industrial Lease between Lessor and Lessee dated April 1, 2002 (the “Addendum”).
SECOND ADDENDUM TO STANDARD INDUSTRIAL LEASEStandard Industrial Lease • May 14th, 2002 • Diagnostic Products Corp • In vitro & in vivo diagnostic substances
This rider to the lease is dated April 1, 2002 and between lessors by Michael Ziering, general partner, 5700 West 96th Street Partnership, and by James Brill, VP Finance and CFO of Diagnostic Products Corporation.
AMENDMENT TO LEASELease • May 10th, 2006 • Diagnostic Products Corp • In vitro & in vivo diagnostic substances
AMENDMENT TO LEASE (the “Amendment”) dated as of April 26, 2006, by and between 5700 WEST 96th STREET, a California general partnership (“Landlord”) and DIAGNOSTIC PRODUCTS CORPORATION, a California corporation (“Tenant”).
DIAGNOSTIC PRODUCTS CORPORATION 1997 STOCK OPTION PLAN INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • November 9th, 2004 • Diagnostic Products Corp • In vitro & in vivo diagnostic substances
DIAGNOSTIC PRODUCTS CORPORATION (the “Corporation”) hereby grants to (the “Optionee”), pursuant to the 1997 Stock Option Plan (the “Plan”), an incentive option to purchase shares of Common Stock, without par value, of the Corporation at a price of $ per share (the “Option”). This Agreement is specifically subject to and governed by all of the terms and conditions of the Plan, as from time to time amended, with the same force and effect as if fully set forth herein. Capitalized terms which have not been defined herein shall have the meanings given them in the Plan. In the event of any conflict between this Agreement and the Plan, the Plan shall govern. A copy of the plan is available for inspection at the Corporation’s executive office.
CHANGE IN CONTROL SEVERANCE AGREEMENTChange in Control Severance Agreement • May 2nd, 2006 • Diagnostic Products Corp • In vitro & in vivo diagnostic substances
THIS CHANGE IN CONTROL SEVERANCE AGREEMENT is made and entered into by and between Diagnostic Products Corporation, a California corporation (hereinafter referred to as the “Company”) and (hereinafter referred to as the “Executive”).
